Genomtec S.A.

Legal Proceedings Report • Nov 19, 2021

Receipt of the decision on granting patent protection for theproprietary set of primers, diagnostic method, and the use of primer setfor HPV infection detection to genetically diagnose HPV16 (Humanpapillomavirus type 16) in the territory of Republic of Poland.TheExecutive Board of Genomtec S.A. ("Company", "Issuer") registered inWroclaw, Poland, hereby reports that the Republic of Poland PatentOffice has positively opiniated to grant the Company a patent protectionfor an invention entitled _quot;A set primers to detect Human papillomavirustype 16, diagnostic method to detect HPV16, use of primer set for HPVinfection detection_quot;.The Issuer informs that this is thefourth patent granted by the Republic of Poland Patent Office and thesixth patent secured by the Company. The Issuer is pending over twentypatent applications globally.HPV 16 is one of the sexuallytransmitted viruses belonging to the human papillomavirus family.Because of its oncogenic properties, it is one of the main causes ofcervical cancer. Early diagnosis of HPV infection will allow promptinitiation of appropriate therapeutic and diagnostic procedures andfurther monitoring of the patient in order to reduce the risk of cancerdevelopment or its rapid diagnosis and further treatment.TheIssuer's Management Board decided that the acknowledgement of the abovepatent is a confidential information, as in the case of an entityoperating on the molecular diagnostics market, it is necessary toeffectively protect intellectual property and designs. Properly securedintellectual property and designs may constitute the Issuer'scompetitive advantage, allowing safer commercialization under conditionthat full protection is ensured on selected markets.In theopinion of the Management Board, a high level of intellectual propertyprotection will also provide the Company with an advantageousnegotiating position before signing any commercial contracts withselected partners as part of the commercialization strategyimplementation.Patent proceedings are aimed at securing keyinterests and are in line with the Issuer's development strategy, whichincludes building a portfolio of intellectual property rights. Diagnosisof viral infections is one of the key areas of technology developed bythe Issuer. For these reasons, in the opinion of the Management Board,this information meets the criteria of confidential informationdescribed in Art. 17 sec. 1 MAR.